Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid…
Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3…
Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and…
As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly…
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine…
Pilots MEDEI’s SMART-TRIAL data management platform to better document the efficacy and safety of its brain network activation technology One…
Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body…
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an…
In February 20th and 22nd and March 15th, Aegle is launching a series of webinars with the objective of demonstrating how the…
Janssen-Cilag International NV (“Janssen”) presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute Psoriasis Area and…
